Beyond Air Inc Stock Price, News & Analysis

Beyond Air (NASDAQ: XAIR) has secured approximately $3.25 million in gross proceeds through the exercise of existing warrants. The agreement involves the immediate exercise of warrants to purchase 1,439,126 shares of common stock at a reduced price of $2.21 per share.

As part of the transaction, the company will issue new unregistered warrants to purchase up to 719,561 shares of common stock at $0.0625 per warrant. These new warrants will have an exercise price of $2.21 per share, with immediate exercisability and a five-year term. The proceeds will support Beyond Air's clinical and pre-clinical programs, operating expenses, and working capital.

NeuroNOS, a subsidiary of Beyond Air (NASDAQ: XAIR), has received FDA Orphan Drug Designation (ODD) for its lead therapy BA-101 in treating Glioblastoma (GBM), an aggressive brain cancer. This marks the company's second ODD and its entry into oncology.

GBM currently has limited treatment options with median survival less than 12 months, and survival rates of less than 20% at two years and less than 10% at five years. The ODD grants several benefits, including seven years of market exclusivity, tax credits for clinical trials, and prescription drug user fee waivers.

The company's approach focuses on NO inhibition strategy, supported by research showing nitric oxide as an important modulator in GBM treatment response.

Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.

Chairman and CEO Steve Lisi will represent the company, with an on-demand presentation webcast available starting September 5, 2025, at 7:00 a.m. ET. Management will also be available for one-on-one investor meetings during the conference.

Beyond Air (NASDAQ: XAIR) has expanded its global distribution network for LungFit PH, a medical device that generates nitric oxide from ambient air. The company has signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador, bringing its total international coverage to 34 countries with a combined population of 2.7 billion people.

In Japan, Beyond Air partnered with AMCO Incorporated, a leading medical device distributor with over 70 years of experience. The LungFit PH system eliminates the need for traditional high-pressure cylinders, offering a more efficient and environmentally friendly solution for hospital settings. Hospital tender submissions are currently in progress in several regions while awaiting regulatory approvals in others.

Beyond Air (NASDAQ: XAIR) reported strong fiscal Q1 2026 results, with revenue surging 157% to $1.8 million compared to $0.7 million in the same period last year. The company secured a significant national group purchasing agreement with Premier, Inc., gaining access to over 4,350 member hospitals and health systems.

The company reaffirmed its FY2026 revenue guidance of $12-16 million. LungFit PH's commercial expansion continues globally, now reaching over 30 countries. Beyond Air reported a net loss of $7.7 million ($1.53 per share) and cash position of $6.5 million as of June 30, 2025. The company recently completed a 1-for-20 reverse stock split to maintain Nasdaq compliance.

Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, has scheduled its first fiscal quarter 2026 financial results conference call for Tuesday, August 12, 2025, at 4:30 PM ET.

The company will discuss its financial performance for the quarter ended June 30, 2025. Investors can access the conference call through domestic (1-877-407-0784) or international (1-201-689-8560) dial-in numbers using conference ID 13754769. A webcast will be available through the company's website, with a replay accessible after the call.

Beyond Air (NASDAQ: XAIR) has secured a national group purchasing agreement with Premier, Inc., effective July 15th, 2025. The agreement enables Premier's network of healthcare providers to access special pricing for Beyond Air's LungFit PH system and disposable NO2 Smart Filters.

The LungFit PH platform utilizes patented Ionizer™ technology to generate unlimited, on-demand nitric oxide from ambient air for ventilator delivery. The system operates on minimal power, equivalent to a 60-watt lightbulb, and includes Smart Filters that provide 12 hours of uninterrupted therapy. Premier serves two-thirds of U.S. healthcare providers, making this agreement significant for Beyond Air's market reach.

Beyond Air reported strong financial results for FY2025, with revenues surging 220% to $3.7M compared to FY2024. The company projects Q1 FY2026 revenue of at least $1.7M and provides FY2026 guidance of $12-16M. LungFit PH, their FDA-approved nitric oxide delivery system, is now installed in over 45 U.S. hospitals and expanding internationally through distribution partnerships covering 2B+ lives. The company submitted a PMA supplement for second-generation LungFit PH and appointed Robert Goodman to the Board. Despite revenue growth, Beyond Air reported a net loss of $46.6M for FY2025, though improved from $60.2M loss in FY2024. Cash position stands at $6.9M with $12.2M in long-term debt as of March 31, 2025.

Beyond Air (NASDAQ: XAIR) has submitted a PMA supplement to the FDA for LungFit PH II, their next-generation nitric oxide (NO) generator. The new system maintains the core functionality of the FDA-approved first generation while being smaller, lighter, and transport-ready. LungFit PH II uses the same Smart Filter and accessories, generating NO from ambient air using patented Ionizer technology. The system delivers NO doses from 0.5-80 ppm for treating PPHN, requiring only the power equivalent to a 60-watt bulb. Key improvements include reduced weight and footprint, simplified operation, longer service intervals, transport compatibility, and an automated backup system. The device aims to treat conditions like PPHN, which affects 1.9 per 1,000 live births with 4-33% mortality rate.